EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

Published:2018-12 Issue: Volume:126 Page:133-138
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

John Thomas,Akamatsu Hiroaki^ORCID,Delmonte Angelo,Su Wu-Chou,Lee Jong Seok,Chang Gee-Chen,Huang Xiangning,Jenkins Suzanne,Wu Yi-Long^ORCID

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann. Oncol.,2016

2. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update;Hanna;J. Clin. Oncol.,2017

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status;BMC Pulmonary Medicine;2024-08-24

2. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

3. Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer;Lung Cancer;2023-12

4. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Taxus chinensis against non-small cell lung cancer;Medicine;2023-11-03

5. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation;Journal of Thoracic Disease;2023-11